SOMERSET, N.J., Nov. 16, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced Neurofenix, a technology-enabled care provider of at-home therapy for stroke survivors, has chosen CareCloud solutions tailored for therapy and rehabilitation practices to streamline workflows, enhance patient engagement, and improve both operational and financial efficiency.
Neurofenix, headquartered in Atlanta, Georgia, is committed to assisting individuals on their path to recovery by maximizing the strength, range of motion, and grip in their arms and hands. Their innovative NeuroPlatfrom, which includes the NeuroBall™ device, a tablet and access to the Neurofenix App, empowers patients to manage occupational therapy from the comfort of their own homes, according to their schedules. Neurofenix is breaking new ground by launching their virtual Upper Limb Stroke Program in the U.S., commencing in Florida, offering telemedicine services coupled with their cutting-edge digital therapy device.
Neurofenix has optimized its new endeavor by integrating talkEHR and CareCloud Breeze, both customized for therapy and rehabilitation practices. These two solutions together provide a comprehensive platform that simplifies billing, streamlines workflows, and enhances patient satisfaction. talkEHR enables top-quality care through streamlined workflows, digital intake, customizable templates, robust compliance tools, and automated reporting. It simplifies work with digitized patient records, centralized details, a user-friendly interface, and smart charting. Breeze enhances patient satisfaction and practice efficiency with advanced engagement features, including automated appointments, online pre-registration, digital intake forms, secure payments, and post-visit surveys, fostering seamless patient-staff communication.
With the adoption of CareCloud's solutions tailored for therapy and rehabilitation practices, Neurofenix is well-positioned to deliver exceptional patient care, streamline operations, and achieve its ambitious goals in the U.S. market.
"We are thrilled to embark on this transformative journey to elevate patient care and broaden our services in collaboration with CareCloud," exclaimed Guillem Singla Buxarrais, chief executive officer of Neurofenix. "Our search for the ideal EHR system led us to CareCloud, where we discovered a solution that not only streamlines our administrative tasks but also offers advanced features such as appointment scheduling, real-time alerts, seamless communication with physicians, patient engagement features, and comprehensive documentation tools. Furthermore, we were delighted to find that CareCloud provides robust billing capabilities, including screening notes to help with Medicare compliance. It seems like the perfect fit for what we are trying to accomplish."
To learn more about how CareCloud is redefining the next generation of technology-enabled revenue cycle solutions, visit carecloud.com.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Company Contact:
Larry Steenvoorden
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.32 |
Daily Change: | -0.18 -7.20 |
Daily Volume: | 76,018 |
Market Cap: | US$37.610M |
August 13, 2024 July 17, 2024 May 14, 2024 April 17, 2024 March 26, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB